@kayysbvby's Wegovy weight loss claim, fact-checked
Quick answer
The video contains no spoken medical claims, but the Wegovy hashtag and caption imply a successful weight loss outcome attributed to semaglutide. Semaglutide 2.4mg (Wegovy) is FDA-approved for chronic weight management and has demonstrated roughly 15% average body weight reduction in pivotal trials, though long-term maintenance typically requires continued use. Patients considering GLP-1 therapy should have a full prescriber evaluation including cardiovascular history, GI tolerance risk, and cost-access planning.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @kayysbvby actually say?
Honestly? Not much that's fact-checkable. The transcript is song lyrics, not a medical monologue. The real message lives in the caption: "I said this my last year being fat" paired with the Wegovy hashtag. That's the claim, and it's an implied one: that Wegovy is what's behind this transformation.
This is a pattern worth paying attention to on TikTok. The actual "claim" is aesthetic and aspirational, not verbal. No dosage mentioned, no mechanism explained, no promise of a specific outcome. But 486,000 views on a post implying Wegovy ends obesity deserves at least a grounded look at what the drug actually does, and what it doesn't.
Does the science back this up?
Semaglutide (Wegovy's active ingredient) has genuinely strong clinical backing for weight loss. This isn't hype. But the real-world results are more complicated than a caption suggests.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults with obesity using 2.4mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks versus 2.4% with placebo. That's a meaningful difference. The SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular outcome data, showing a 20% reduction in major adverse cardiac events in people with obesity and established cardiovascular disease.
So yes, Wegovy works. But "my last year being fat" sets an expectation that weight loss is linear, permanent, and complete. The STEP 1 data also showed that most participants regained two-thirds of lost weight within a year of stopping the drug (Wilding et al., 2022, Diabetes, Obesity and Metabolism). The drug doesn't cure obesity. It manages it, often requiring long-term use.
What did they get wrong (or right)?
Credit where it's due: there's nothing medically wrong in this video. No dangerous dosing advice, no fake mechanism claims, no selling compounded knockoffs as equivalent to the brand name. The creator didn't say anything false because they barely said anything at all about the drug.
What's worth pushing back on is the framing. Declaring a "last year being fat" implies a finish line that the clinical literature doesn't really support. Obesity is a chronic condition with a biological basis, not a phase you complete and exit. The GLP-1 receptor agonist space has a visibility problem where success stories dominate and the dropout rates, side effect profiles, and rebound data stay quiet.
About 40-50% of patients discontinue semaglutide within the first year in real-world settings (Khera et al., 2023, JAMA Internal Medicine). Nausea, vomiting, and gastrointestinal side effects are the most common reasons. That context doesn't make the drug bad, but it matters when 486,000 people are watching an unreservedly optimistic caption.
What should you actually know?
If you're considering Wegovy because a video made it look like the obvious answer, here are the things that don't make it into captions. Wegovy is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. It requires a prescription and ongoing medical supervision.
The drug works by mimicking GLP-1, a gut hormone that regulates appetite and blood sugar. It slows gastric emptying and acts on brain receptors involved in satiety. It is not a metabolism booster or a fat burner in the traditional sense. It reduces appetite. Consistently. Over time. That's the mechanism.
Cost and access remain real barriers. Wegovy's list price sits around $1,300 per month in the US without insurance coverage. Insurance coverage is inconsistent. And the rise of compounded semaglutide, which is not the same as FDA-approved Wegovy, has created a parallel market with significant quality control concerns. The FDA has flagged compounded semaglutide safety issues repeatedly since 2023.
If this video inspires you to talk to a doctor about GLP-1 options, that's a reasonable next step. If it makes you feel like you just need to find the product and start, that's where things get risky.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @kayysbvby's Wegovy weight loss claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The video contains no spoken medical claims, but the Wegovy hashtag and caption imply a successful weight loss outcome attributed to semaglutide.
FormBlends verdict
The video contains no spoken medical claims, but the Wegovy hashtag and caption imply a successful weight loss outcome attributed to semaglutide. Semaglutide 2.4mg (Wegovy) is FDA-approved for chronic weight management and has demonstrated roughly 15% average body weight reduction in pivotal trials, though long-term maintenance typically requires continued use. Patients considering GLP-1 therapy should have a full prescriber evaluation including cardiovascular history, GI tolerance risk, and cost-access planning.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video contains no spoken medical claims, but the Wegovy hashtag and caption imply a successful weight loss outcome attributed to semaglutide. Semaglutide 2.4mg (Wegovy) is FDA-approved for chronic weight management and has demonstrated roughly 15% average body weight reduction in pivotal trials, though long-term maintenance typically requires continued use. Patients considering GLP-1 therapy should have a full prescriber evaluation including cardiovascular history, GI tolerance risk, and cost-access planning.
- STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide 2.4mg produced average 14.9% body weight loss over 68 weeks, compared to 2.4% with placebo.
- Wilding et al. (2022, Diabetes, Obesity and Metabolism): patients regained roughly two-thirds of lost weight within one year of stopping Wegovy, making it a long-term management drug, not a cure.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide 2.4mg produced average 14.9% body weight loss over 68 weeks, compared to 2.4% with placebo.
- Wilding et al. (2022, Diabetes, Obesity and Metabolism): patients regained roughly two-thirds of lost weight within one year of stopping Wegovy, making it a long-term management drug, not a cure.
- Khera et al. (2023, JAMA Internal Medicine): approximately 40-50% of real-world patients discontinue semaglutide within the first year, most commonly due to gastrointestinal side effects.
- SELECT trial (Lincoff et al., 2023, NEJM): semaglutide reduced major adverse cardiac events by 20% in people with obesity and established cardiovascular disease, extending its clinical value beyond weight alone.
- Wegovy's US list price is approximately $1,300 per month without insurance, and coverage remains inconsistent across payers.
- The FDA has issued multiple safety communications about compounded semaglutide products since 2023; compounded versions are not equivalent to FDA-approved Wegovy.
- Wegovy is FDA-approved for BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition; a prescription and medical supervision are required.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
kaybabbyyᥫ᭡ · TikTok creator
486.3K views on this video
I said this my last year being fat😂😂🤏🏾#fyp #wegovy #bye
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by kaybabbyyᥫ᭡, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.